



FOR IMMEDIATE RELEASE

SPARC to Provide Update on Taclantis™ NDA

MUMBAI – February 13, 2020, Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) on Monday, March 2, 2020, will host a conference call to provide an update on Taclantis™ (Paclitaxel Injection Concentrate for Suspension) NDA (New Drug Application) status. This conference call, scheduled at 4:00 PM IST, will be reachable through an audio dial-in.

Audio conference

Participants can dial-in on the number below:

Universal Dial In	+91 22 6280 1278 +91 22 7115 8179
India National Toll Free	1 800 120 1221 1 800 266 1221
International Toll Free	
Hong Kong	800964448
Singapore	8001012045
UK	08081011573
USA	18667462133

To participate in the conference call, please dial in the number provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call.

About SPARC (CIN: L73100GJ2006PLC047837):

Sun Pharma Advanced Research Company Ltd. (SPARC) is a global pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC aims to consistently lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at www.sparc.life

Contacts:

Jaydeep Issrani
Tel +91 22 66455645, Extn: 5787
Tel Direct +91 22 6645 5787
Mobile +91-9820216916
E mail jaydeep.issrani@sparcmail.com

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life

Registered Office : SPARC, Akota Road, Akota, Vadodara - 390 020, Gujarat, India.